Image default

‘We are still without peers in biosimilars’

We have invested in multiple manufacturing techniques and technologies to improve our productivity. The enhanced use of digital and automation technology has reduced the need for manual intervention and led to faster turn-around times.

Related posts

India’s 100 unicorns valued at $333 billion


Vivo Y33s: A good blend of style and substance


Pushp Kumar Joshi takes over as CMD of HPCL


Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy